AR075530A1 - Nuevas orto-aminoamidas para el tratamiento del cancer - Google Patents

Nuevas orto-aminoamidas para el tratamiento del cancer

Info

Publication number
AR075530A1
AR075530A1 ARP100100498A ARP100100498A AR075530A1 AR 075530 A1 AR075530 A1 AR 075530A1 AR P100100498 A ARP100100498 A AR P100100498A AR P100100498 A ARP100100498 A AR P100100498A AR 075530 A1 AR075530 A1 AR 075530A1
Authority
AR
Argentina
Prior art keywords
cyano
unsubstituted
halogen
compounds
lower alkoxy
Prior art date
Application number
ARP100100498A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR075530A1 publication Critical patent/AR075530A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procesos para la fabricacion de dichos compuestos así como a medicamentos que contienen dichos compuestos. Los compuestos de esta invencion poseen actividad antiproliferaliva e inductora de la diferenciacion y por ello son utiles para el tratamiento de enfermedades como el cáncer en seres humanos o en animales. Reivindicacion 1: Los compuestos de la formula (1) en la que R es grupo de formulas (2); R1 es benzoimidazolilo, sin sustituir o sustituido por halogeno, alquilo interior, alcoxi inferior, ciano, -OCF2H, -OCF3, trifluormetilo o cicloalquilo; -CO-NH-R3, en el que R3 es arilo o heteroarilo, sin sustituir o sustituido una, dos o tres veces por halogeno, alquilo inferior, alcoxi inferior, ciano, -OCF2H, -OCF3, trifluormetilo o cicloalquilo; o (3) en el que R4 es arilo, sin sustituir o sustituido por halogeno, alquilo inferior, alcoxi inferior, ciano, -OCF2H, -OCF3, trifluormetilo, o cicloalquilo; R2 es alquilo inferior, heterociclilo o heteroarilo, sin sustituir o sustituidos una, dos o tres veces por halogeno, fenilo, ciano, hidroxi o alcoxi inferior; y las sales farmacéuticamente activas, mezclas racémicas, enantiomeros, isomeros opticos o formas tautomeras de los mismos; con la condicion de que se excluyan los isomeros cis de la formula (1).
ARP100100498A 2009-02-23 2010-02-19 Nuevas orto-aminoamidas para el tratamiento del cancer AR075530A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09153445 2009-02-23
EP09157150 2009-04-02

Publications (1)

Publication Number Publication Date
AR075530A1 true AR075530A1 (es) 2011-04-06

Family

ID=42102214

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100498A AR075530A1 (es) 2009-02-23 2010-02-19 Nuevas orto-aminoamidas para el tratamiento del cancer

Country Status (14)

Country Link
US (1) US7977372B2 (es)
EP (1) EP2398769A1 (es)
JP (1) JP2012518612A (es)
KR (1) KR20110117194A (es)
CN (1) CN102300845A (es)
AR (1) AR075530A1 (es)
AU (1) AU2010215524A1 (es)
BR (1) BRPI1007995A2 (es)
CA (1) CA2751777A1 (es)
IL (1) IL213761A0 (es)
MX (1) MX2011008899A (es)
SG (1) SG173672A1 (es)
TW (1) TW201032800A (es)
WO (1) WO2010094678A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028192A1 (en) 2008-09-03 2010-03-11 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
DK2680694T3 (en) 2011-02-28 2019-03-25 Biomarin Pharm Inc HISTONDEACETYLASE INHIBITORS
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2712655B1 (en) 2011-04-28 2019-12-18 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9790184B2 (en) 2012-07-27 2017-10-17 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
CA2903490C (en) 2013-03-15 2021-04-13 Biomarin Pharmaceutical Inc. Hdac inhibitors
JP6008201B2 (ja) * 2013-05-10 2016-10-19 東レ・ファインケミカル株式会社 スチレン誘導体の製造方法
TN2016000210A1 (en) 2013-11-28 2017-10-06 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof.
BR112017009701B1 (pt) * 2014-12-08 2021-09-08 Fmc Corporation Composto e métodos de preparação de compostos
IL277044B2 (en) 2018-03-05 2023-10-01 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1033046B (it) 1970-10-31 1979-07-10 Finotto Martino Procedimento di fabbricazione di benzimidazoli sostituiti
DE2201062A1 (de) * 1972-01-11 1973-07-26 Bayer Ag N-alkoxycarbonyl- bzw. n-alkylthiocarbonyl-2-(2'-thienyl)-benzimidazole, ein verfahren zu ihrer herstellung und ihre verwendung als fungizide
WO2001038322A1 (en) 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
US7208491B2 (en) * 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
US7868205B2 (en) * 2003-09-24 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
JP5319113B2 (ja) * 2004-03-26 2013-10-16 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
WO2006115845A1 (en) 2005-04-20 2006-11-02 Merck & Co., Inc. Benzothiophene derivatives
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
AU2007221207A1 (en) 2006-02-28 2007-09-07 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
MX2010012297A (es) * 2008-05-16 2010-12-06 Hoffmann La Roche Nuevas n-(2-amino-fenil)-acrilamidas.

Also Published As

Publication number Publication date
MX2011008899A (es) 2011-09-15
WO2010094678A1 (en) 2010-08-26
CN102300845A (zh) 2011-12-28
AU2010215524A1 (en) 2011-06-30
JP2012518612A (ja) 2012-08-16
IL213761A0 (en) 2011-07-31
US20100216806A1 (en) 2010-08-26
BRPI1007995A2 (pt) 2019-09-24
US7977372B2 (en) 2011-07-12
CA2751777A1 (en) 2010-08-26
EP2398769A1 (en) 2011-12-28
KR20110117194A (ko) 2011-10-26
TW201032800A (en) 2010-09-16
SG173672A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
AR075530A1 (es) Nuevas orto-aminoamidas para el tratamiento del cancer
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
CR20170316A (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
ECSP11010804A (es) Compuestos orgánicos
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
PE20150666A1 (es) Inhibidores de serina/treonina cinasa
PE20141191A1 (es) Compuestos como inhibidores de bace
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
UY31878A (es) Miméticos de glucocorticoides, métodos para su fabriciación, composiciones farmacéuticas y usos de los mismos
PE20150669A1 (es) Derivados de benzamida para la inhibicion de la actividad de abl1, abl2 y bcr-abl1
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
CR11620A (es) Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
CU24327B1 (es) Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
AR071531A1 (es) Compuesto cristalino heteromonociclico
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CO6390058A2 (es) Piperidina espiro pirrolidinona y piperidinona sustituidas usadas como moduladores de h3

Legal Events

Date Code Title Description
FB Suspension of granting procedure